Syenza News — health technology assessment, market access and health economics
FDA Rare Disease Framework Initiative Would Tailor Review to Small Populations
What steps is the FDA taking to accelerate rare disease treatments?
The FDA’s new Rare Disease Framework Initiative aims to streamline regulatory pathways, enhance collaboration with sponsors, and improve patient access to innovative therapies.
Explore how this could reshape drug development for underserved patient populations.
#SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #healthcarepolicy
Recent Posts
Semaglutide for Opioid Use Disorder: $13.3M Trial Planned in Allegheny County
Oct 15
AI guidance in clinical development: what industry is asking for
Oct 15
Social prescribing in Portugal: pilots, gaps and the cost of time
Oct 15
EMA Expert Panel Consultation for Medical Devices Adds an Orphan Pathway
Oct 14
BNT113 head and neck cancer trial misses first endpoint
Oct 14Syenza's Top Picks
BD US Government Partnership Commits $19 Billion to US Manufacturing
Oct 7, 2026
FuturePHARMA Targets Local Pharmaceutical Manufacturing in South Africa
Oct 8, 2026
PhRMA’s GLOBE Drug Pricing Lawsuit Seeks to Block the Medicare Rule
Oct 8, 2026
Dutch Court Grants Keytruda SC Injunction in Eight European Markets
Oct 8, 2026
Liver Cancer Burden in Portugal Set to Claim 6,600 Lives by 2027
Oct 8, 2026
Biosimilar Uptake Policies Work Only as a Mix, Observatory Says
Oct 8, 2026
Latest News
Cost Effectiveness Analysis
Rapid-Acting Insulin Analogue Cost-Effectiveness in Type 1 Diabetes: What the Evidence Shows
Insulin analogue cost-effectiveness studies for adults with type 1 diabetes mostly point the same way: the newer products usually come out ahead of human insulin. A new systematic review says that headline rests on thinner ground than it looks. The paper, by Shiwa Yaghoubi Bina, Steve Njokuocha and the T1D Economic Evidence Synthesis Group, has been accepted for Value in Health. The version available now is a pre-proof, so figures could still change at copyediting. The World Health Organization funded […]
Clinical Practice
Denosumab Ascend Biosimilar Wins EU Authorisation for Bone Complications
The EMA has authorised Denosumab Ascend, a biosimilar of Xgeva. Here is what the assessment shows on safety, efficacy and use. #SyenzaNews #biotechnology #MarketAccess
Europe
Health Security in Europe: Why Resilience Starts Before a Crisis
Health security in Europe is being redefined from emergency response to national resilience, and the EFPIA View argues it starts with funded health systems.
Health Policy
Health Investment Returns: What Berlin’s Funding the Future Panel Argued
Ministers, development banks and industry at the World Health Summit argued that health investment returns should be measured in lives saved, jobs and tax revenue, not budget size. #SyenzaNews #HealthEconomics #MarketAccess
Clinical Guidelines And Protocols
Individualised Genetic Therapies Test Regulation, Payment and HTA
OHE’s A Dose of Economics explores why medicines made for one patient challenge regulation, payment and HTA.
Europe
The Strategic Health Economy: Why Finance Ministries Still See Health as a Cost
At the World Health Summit in Berlin, speakers from the European Commission, Japan, Africa, the Asian Development Bank and industry argued that health is a strategic economic asset, and asked how to persuade finance ministries. #SyenzaNews #HealthEconomics
Artificial Intelligence And Machine Learning
AI in Medical Education: Responsible Integration Across the Training Continuum
AI is entering every stage of medical training. A new npj Digital Medicine Perspective maps how to integrate it responsibly across UGME, GME and CME.
Diseases
Multiple Sclerosis Health Utilities Decline With Disability
Health utilities for multiple sclerosis fall with disability, and progressive forms score lowest. A UK cohort of 5,772 patients gives modellers EQ-5D and cost inputs by MS type and EDSS band. #SyenzaNews #MarketAccess
Clinical Practice
Clinical trial applications advice becomes permanent from 2027
The EU’s ACT EU advice pilot for clinical trial applications becomes permanent in January 2027, with updated sponsor guidance.
Diseases
Uptake of New Cancer Medicines in Europe Still Varies
Uptake of new cancer medicines in Europe still varies, with a three-fold gap between countries in 2023.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.
